DBV Technologies: Bryan Garnier cuts target price.
(CercleFinance.com) - In a report released on Tuesday, Bryan Garnier reduced its target price on DBV Technologies from 105 euros to 86 euros, while confirming its "buy" rating.
With the stock collapsing over 40%, hammered in the market for mixed results for PEPITES (Peanut EPIT Efficacy and Safety), a phase III study to assess the efficacy and safety of use of Viaskin Peanut in children of 4 to 11 years old, the broker considers this reaction as over-exaggerated.
The broker states that it still believe that Viaskin Peanut will be firmly approved by the US FDA. Stallergenes Oralair and ALK Abello Odactra have indeed all three experienced such a misfortune before obtaining such FDA approval, it points out.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
With the stock collapsing over 40%, hammered in the market for mixed results for PEPITES (Peanut EPIT Efficacy and Safety), a phase III study to assess the efficacy and safety of use of Viaskin Peanut in children of 4 to 11 years old, the broker considers this reaction as over-exaggerated.
The broker states that it still believe that Viaskin Peanut will be firmly approved by the US FDA. Stallergenes Oralair and ALK Abello Odactra have indeed all three experienced such a misfortune before obtaining such FDA approval, it points out.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.